351 related articles for article (PubMed ID: 18477770)
41. Efficacy of molecular response at 1 or 3 months after the initiation of dasatinib treatment can predict an improved response to dasatinib in imatinib-resistant or imatinib-intolerant Japanese patients with chronic myelogenous leukemia during the chronic phase.
Inokuchi K; Kumagai T; Matsuki E; Ohashi K; Shinagawa A; Hatta Y; Takeuchi J; Yoshida C; Wakita H; Kozai Y; Shirasugi Y; Fujisawa S; Iwase O; Yano S; Okamoto S; Oba K; Sakamoto J; Sakamaki H
J Clin Exp Hematop; 2014; 54(3):197-204. PubMed ID: 25501110
[TBL] [Abstract][Full Text] [Related]
42. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis.
Verstovsek S; Tefferi A; Cortes J; O'Brien S; Garcia-Manero G; Pardanani A; Akin C; Faderl S; Manshouri T; Thomas D; Kantarjian H
Clin Cancer Res; 2008 Jun; 14(12):3906-15. PubMed ID: 18559612
[TBL] [Abstract][Full Text] [Related]
43. A once-daily dasatinib dosing strategy for chronic myeloid leukemia.
Bryant G
Clin J Oncol Nurs; 2009 Jun; 13(3):316-23. PubMed ID: 19502190
[TBL] [Abstract][Full Text] [Related]
44. Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure.
Hochhaus A
Expert Opin Pharmacother; 2007 Dec; 8(18):3257-64. PubMed ID: 18035968
[TBL] [Abstract][Full Text] [Related]
45. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
[TBL] [Abstract][Full Text] [Related]
46. Dasatinib induces autophagy in mice with Bcr-Abl-positive leukemia.
Morita M; Nishinaka Y; Kato I; Saida S; Hiramatsu H; Kamikubo Y; Heike T; Nakahata T; Adachi S
Int J Hematol; 2017 Mar; 105(3):335-340. PubMed ID: 27848186
[TBL] [Abstract][Full Text] [Related]
47. Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back.
von Bubnoff N; Peschel C; Duyster J
Leukemia; 2003 May; 17(5):829-38. PubMed ID: 12750693
[TBL] [Abstract][Full Text] [Related]
48. [Dasatinib. A novel tyrosine kinase inhibitor for the treatment of chronic myeloid leukaemia].
Bjerrum OW; Dufva IH; Stentoft J; Hasselbalch HC
Ugeskr Laeger; 2008 Jan; 170(5):331-3. PubMed ID: 18252160
[TBL] [Abstract][Full Text] [Related]
49. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.
Soverini S; De Benedittis C; Papayannidis C; Paolini S; Venturi C; Iacobucci I; Luppi M; Bresciani P; Salvucci M; Russo D; Sica S; Orlandi E; Intermesoli T; Gozzini A; Bonifacio M; Rigolin GM; Pane F; Baccarani M; Cavo M; Martinelli G
Cancer; 2014 Apr; 120(7):1002-9. PubMed ID: 24382642
[TBL] [Abstract][Full Text] [Related]
50. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
Hochhaus A; Baccarani M; Deininger M; Apperley JF; Lipton JH; Goldberg SL; Corm S; Shah NP; Cervantes F; Silver RT; Niederwieser D; Stone RM; Dombret H; Larson RA; Roy L; Hughes T; Müller MC; Ezzeddine R; Countouriotis AM; Kantarjian HM
Leukemia; 2008 Jun; 22(6):1200-6. PubMed ID: 18401416
[TBL] [Abstract][Full Text] [Related]
51. Dasatinib maintenance therapy after allogeneic hematopoietic stem cell transplantation for an isolated central nervous system blast crisis in chronic myelogenous leukemia.
Nishimoto M; Nakamae H; Koh KR; Kosaka S; Matsumoto K; Morita K; Koh H; Nakane T; Ohsawa M; Hino M
Acta Haematol; 2013; 130(2):111-4. PubMed ID: 23548721
[TBL] [Abstract][Full Text] [Related]
52. Dasatinib: a new step in molecular target therapy.
Olivieri A; Manzione L
Ann Oncol; 2007 Jun; 18 Suppl 6():vi42-6. PubMed ID: 17591830
[TBL] [Abstract][Full Text] [Related]
53. Isolated central nervous system relapse in patient with blast-crisis chronic myeloid leukemia in durable complete cytogenetic remission on dasatinib treatment: pharmacokinetics and ABL mutation analysis in cerebrospinal fluid.
Zhou HS; Dai M; Wei Y; Wang Q; Xu N; Yin C; Meng F
Leuk Lymphoma; 2013 Jul; 54(7):1557-9. PubMed ID: 23194002
[No Abstract] [Full Text] [Related]
54. Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate.
Pfeifer H; Wassmann B; Hofmann WK; Komor M; Scheuring U; Brück P; Binckebanck A; Schleyer E; Gökbuget N; Wolff T; Lübbert M; Leimer L; Gschaidmeier H; Hoelzer D; Ottmann OG
Clin Cancer Res; 2003 Oct; 9(13):4674-81. PubMed ID: 14581336
[TBL] [Abstract][Full Text] [Related]
55. Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
Shen S; Chen X; Cai J; Yu J; Gao J; Hu S; Zhai X; Liang C; Ju X; Jiang H; Jin R; Wu X; Wang N; Tian X; Pan K; Jiang H; Sun L; Fang Y; Li CK; Hu Q; Yang M; Zhu Y; Zhang H; Li C; Pei D; Jeha S; Yang JJ; Cheng C; Tang J; Zhu X; Pui CH
JAMA Oncol; 2020 Mar; 6(3):358-366. PubMed ID: 31944221
[TBL] [Abstract][Full Text] [Related]
56. Dasatinib: is it all in the dose?
Condorelli F; Genazzani AA
BioDrugs; 2010 Jun; 24(3):157-63. PubMed ID: 20222756
[TBL] [Abstract][Full Text] [Related]
57. Dasatinib: BMS 354825.
Drugs R D; 2006; 7(2):129-32. PubMed ID: 16542059
[TBL] [Abstract][Full Text] [Related]
58. Successful second allogeneic stem cell transplantation in second remission induced by dasatinib in a child with Philadelphia chromosome positive acute lymphoblastic leukemia.
Millot F; Cividin M; Brizard F; Chomel JC; Méchinaud F; Guilhot F
Pediatr Blood Cancer; 2009 Jul; 52(7):891-2. PubMed ID: 19202569
[TBL] [Abstract][Full Text] [Related]
59. Systemic dasatinib fails to prevent development of central nervous system progression in a patient with BCR-ABL unmutated Philadelphia chromosome-positive leukemia.
Frigeri F; Arcamone M; Luciano L; Di Francia R; Pane F; Pinto A
Blood; 2009 May; 113(20):5028-9. PubMed ID: 19443672
[No Abstract] [Full Text] [Related]
60. The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia.
Wolff NC; Richardson JA; Egorin M; Ilaria RL
Blood; 2003 Jun; 101(12):5010-3. PubMed ID: 12595307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
